Literature DB >> 1360025

Effect of modification of the basic residues of dynorphin A-(1-13) amide on kappa opioid receptor selectivity and opioid activity.

K R Snyder1, S C Story, M E Heidt, T F Murray, G E DeLander, J V Aldrich.   

Abstract

A series of dynorphin A-(1-13) amide (Dyn A-(1-13)NH2) analogues containing lysine or N epsilon-acetyllysine (Lys(Ac)) was prepared by solid-phase peptide synthesis and evaluated for opioid receptor affinity in radioligand binding assays and for opioid activity in the guinea pig ileum (GPI). Substitutions were made at positions 6, 7, 9, 11, and 13, the basic amino acids in the C-terminus of the peptide, in order to assess the individual contributions of these residues to the kappa opioid receptor affinity and selectivity of Dyn A-(1-13)NH2. While substitutions of Lys(Ac) for Arg in position 6 did not affect kappa receptor affinity, it enhanced affinity for mu and delta receptors and therefore caused a loss of kappa receptor selectivity. When Lys(Ac) was substituted for Arg9, kappa opioid receptor affinity was enhanced and kappa receptor selectivity was retained. Replacement for Arg7, Lys11, or Lys13 by Lys(Ac) resulted in both decreased affinity and selectivity for kappa receptors. These results demonstrate the importance of Arg6 to the receptor selectivity profile of Dyn A-(1-13)NH2 and indicate that, of the five basic residues in the C-terminus, only Arg9 can be replaced by a nonbasic residue without substantial loss of kappa opioid receptor selectivity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1360025     DOI: 10.1021/jm00101a010

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Characterization of peptide-oligonucleotide heteroconjugates by mass spectrometry.

Authors:  O N Jensen; S Kulkarni; J V Aldrich; D F Barofsky
Journal:  Nucleic Acids Res       Date:  1996-10-01       Impact factor: 16.971

2.  Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands.

Authors:  M F Bird; R S Vardanyan; V J Hruby; G Calò; R Guerrini; S Salvadori; C Trapella; J McDonald; D J Rowbotham; D G Lambert
Journal:  Br J Anaesth       Date:  2015-02-13       Impact factor: 9.166

3.  Structure-Activity Relationships of [des-Arg7]Dynorphin A Analogues at the κ Opioid Receptor.

Authors:  Cyf N Ramos-Colon; Yeon Sun Lee; Michael Remesic; Sara M Hall; Justin LaVigne; Peg Davis; Alexander J Sandweiss; Mary I McIntosh; Jessica Hanson; Tally M Largent-Milnes; Todd W Vanderah; John Streicher; Frank Porreca; Victor J Hruby
Journal:  J Med Chem       Date:  2016-11-08       Impact factor: 7.446

4.  Molecular dynamics simulations predict a tilted orientation for the helical region of dynorphin A(1-17) in dimyristoylphosphatidylcholine bilayers.

Authors:  R Sankararamakrishnan; H Weinstein
Journal:  Biophys J       Date:  2000-11       Impact factor: 4.033

5.  Effect of anchoring 4-anilidopiperidines to opioid peptides.

Authors:  Ravil R Petrov; Yeon Sun Lee; Ruben S Vardanyan; Lu Liu; Shou-wu Ma; Peg Davis; Josephine Lai; Frank Porreca; Todd W Vanderah; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2013-04-03       Impact factor: 2.823

6.  Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides.

Authors:  S Salvadori; M Attila; G Balboni; C Bianchi; S D Bryant; O Crescenzi; R Guerrini; D Picone; T Tancredi; P A Temussi
Journal:  Mol Med       Date:  1995-09       Impact factor: 6.354

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.